샘플 요청 목록

 카트 문의
시장보고서
상품코드
1798216

세계의 처방 피부과 치료제 시장

Prescription Dermatology Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 280 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 처방 피부과 치료제 시장은 2030년까지 808억 달러에 달할 전망

2024년에 504억 달러로 추정되는 세계의 처방 피부과 치료제 시장은 분석 기간인 2024-2030년에 CAGR 8.2%로 성장하며, 2030년에는 808억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 여드름·주사 치료제는 CAGR 10.4%를 기록하며, 분석 기간 종료시에는 223억 달러에 달할 것으로 예측됩니다. 건선 치료제 부문의 성장률은 분석 기간 중 CAGR 9.4%로 추정됩니다.

미국 시장은 137억 달러로 추정, 중국은 CAGR 13.1%로 성장 예측

미국의 처방 피부과 치료제 시장은 2024년에 137억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 177억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 13.1%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 4.0%와 7.9%로 예측됩니다. 유럽에서는 독일이 CAGR 5.5%로 성장할 것으로 예측됩니다.

세계의 처방 피부과 치료제 시장 - 주요 동향과 촉진요인 정리

처방전 기반 피부과 치료로의 전환을 촉진하는 요인은 무엇인가?

처방 피부과 치료제는 의료적 개입이 필요한 중등도에서 중증의 피부 질환을 치료하기 위해 고안된 치료 카테고리로 성장하고 있습니다. 시중에서 판매되는 스킨케어 제품과는 달리 건선, 아토피 피부염, 주사, 여드름, 여드름, 농포성 땀샘염, 피부암 등 만성, 염증성, 감염성, 자가면역성 피부질환을 치료하는 데 사용됩니다. 피부 건강에 대한 인식이 높아지고, 피부과 의료에 대한 접근성이 향상되고, 질병 유병률이 증가함에 따라 지난 10년간 시장이 크게 성장했습니다.

지속성 또는 난치성 질환 환자에게는 고급 외용제, 경구용 레티노이드, 생물제제, 전신 면역조절제 등이 처방되는 경우가 많습니다. 미용피부과와 치료피부과의 경계도 모호해지고 있으며, 색소침착장애, 탈모, 광과민증에 대한 임상적으로 효과적인 해결책을 찾는 환자들이 증가하고 있습니다. 사회의 태도가 적극적인 피부 관리로 바뀌면서 과거에는 '미용상의 골칫거리'로 여겨졌던 증상도 의료의 영역으로 임베디드되고 있습니다.

피부과 의사, 일반 내과 의사, 알레르기 전문의를 포함한 의료 서비스 프로바이더들도 질환에 대한 인식이 높아지고 진단 툴이 개선됨에 따라 전문 제품을 처방하는 경향이 증가하고 있습니다. 보험 적용 확대, 피부과 방문 환자 증가, 디지털 처방 플랫폼 등의 요인이 처방전 이동률을 높이고 처방 준수율을 향상시키고 있습니다.

어떤 과학적 진보와 분자 혁신이 치료 옵션을 재구성하고 있는가?

처방 피부과 시장에서는 치료 효과와 안전성 프로파일을 향상시키는 새로운 원료의약품(API), 표적 생물제제, 전달 시스템이 급증하고 있습니다. 코르티코스테로이드, 레티노이드, 항생제와 같은 기존 약물은 현재 더 나은 질병 조절과 적은 부작용을 제공하는 새로운 면역 조절제, 선택적 JAK 억제제, 인터류킨 표적 단클론 항체, 인터류킨 표적 항체 등으로 보완되거나 대체되고 있습니다.

듀피루맙(아토피피부염 치료제), 세쿠누맙(건선 치료제), 아달리무맙(농포성 땀샘염 치료제) 등의 생물제제는 외용제가 듣지 않는 중증 환자들의 치료 성적을 획기적으로 개선했습니다. PDE4 억제제, TYK2 차단제 등 저분자 치료제도 특히 생물제제 불내성 환자나 증상이 경미한 환자를 대상으로 평가 및 상용화되고 있습니다. 바이오시밀러의 등장으로 치료비용이 절감되고, 다양한 지역에서의 접근성이 향상되고 있습니다.

제형 기술도 발전하여 마이크로스피어 전달, 폼 기반 비히클, 나노 캐리어를 강화한 외용제로 피부 침투성, 안정성, 환자 순응도가 향상되고 있습니다. 기업은 특히 지루성 피부염이나 약물 내성 여드름과 같은 치료 저항성 질환에 대해 약리유전체 스크리닝과 AI를 통한 치료 매칭을 통한 개인맞춤형 피부과학에 대한 투자를 진행하고 있습니다.

시장 역학을 형성하는 환자 부문, 병태, 채널은 무엇인가?

10대와 젊은 성인은 여드름과 여드름 관련 흉터의 확산으로 인해 처방전 피부과 시장의 큰 비중을 차지하고 있습니다. 성인층, 특히 30-55세 연령층은 주사, 기미, 간반, 만성 두드러기 등의 치료 영역의 성장에 기여하고 있습니다. 당뇨, 면역력 저하 등의 합병증을 앓고 있는 고령층은 항진균제, 항바이러스제, 항염증약 등 피부과 치료제 수요를 견인하고 있습니다.

가장 빠르게 성장하고 있는 치료 분야는 아토피피부염, 건선, 피부암 등입니다. 환경적 스트레스 요인, 자가면역 유발 요인, 생활습관의 변화는 전 세계에서 만성 피부질환을 악화시키고 있습니다. 도시화, 공해, 장시간 스크린에 노출되는 것도 산화 스트레스와 광노화 관련 피부 질환의 원인이 되고 있습니다.

처방전 조제는 점점 더 디지털 약국 및 전문 약국 채널로 이동하고 있습니다. 원격 피부과는 특히 서비스가 부족한 오지 시장에서 진단과 치료 시작에 있으며, 중심적인 역할을 하고 있습니다. 전문 약국, 피부과 전문 체인, 디지털 플랫폼은 자동 리필, 가상 진료, AI를 활용한 증상 추적을 통해 컴플라이언스를 개선하고 있습니다.

세계 처방 피부과 치료제 시장의 성장을 주도하는 요인은 무엇인가?

세계 처방 피부과 치료제 시장의 성장 원동력은 만성 피부질환의 유병률 증가, 피부과 전문의의 저변 확대, 약물 분자 및 전달 메커니즘의 강력한 기술 혁신입니다. 피부 건강이 전신 건강 및 삶의 질의 핵심으로 여겨지면서 효과적이고 의학적으로 관리되는 치료에 대한 환자들의 요구가 증가하고 있습니다.

차세대 생물제제 및 면역치료제의 상용화로 치료 프로토콜이 재구성되어 보다 신속한 질병 통제, 재발률 감소, 환자 결과 개선이 이루어지고 있습니다. 바이오시밀러와 새로운 외용제에 대한 규제 당국의 승인은 저렴한 가격과 지역적 접근성의 확대를 가져오고 있습니다. 또한 임상시험 및 피부과 연구개발 파이프라인에 대한 투자 확대로 치료의 다양성이 증가하고 있습니다.

소비자 디지털화와 원격의료의 도입은 처방전 온보딩, 리필 물류, 순응도 모니터링의 성장을 지원하고 있습니다. 아시아태평양 및 라틴아메리카 시장은 피부과 인프라의 성장, 가처분 소득 증가, 피부과 의료에 대한 인식 증가로 인해 강력한 모멘텀을 보이고 있습니다. 기술 혁신, 디지털 헬스, 환자 중심 모델이 융합되면서 향후 10년간 처방 피부과 치료제 시장은 전 세계에서 강력한 성장세를 보일 것으로 예측됩니다.

부문

제품 유형(여드름·주사 치료제, 건선 치료제, 피부염·지방과다분비 치료제, 진균 감염증 치료제, 피부암 치료제, 기타 제품 유형), 유통 채널(병원 약국, 소매 약국, 통판 약국)

조사 대상 기업의 예

  • AbbVie Inc.
  • Almirall S.A.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Biofrontera AG
  • Cassiopea SpA(Cosmo Pharma)
  • Cipher Pharmaceuticals
  • Dermira, Inc.(a Lilly company)
  • Dr. Reddy's Laboratories
  • Galderma S.A.
  • Glenmark Pharmaceuticals
  • Leo Pharma A/S
  • Maruho Co., Ltd.
  • Mayne Pharma Group Ltd
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries
  • Viatris Inc.

AI 통합

당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계 고유 SLM를 쿼리 하는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.09.04

Global Prescription Dermatology Therapeutics Market to Reach US$80.8 Billion by 2030

The global market for Prescription Dermatology Therapeutics estimated at US$50.4 Billion in the year 2024, is expected to reach US$80.8 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2024-2030. Acne & Rosacea Drugs, one of the segments analyzed in the report, is expected to record a 10.4% CAGR and reach US$22.3 Billion by the end of the analysis period. Growth in the Psoriasis Drugs segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.7 Billion While China is Forecast to Grow at 13.1% CAGR

The Prescription Dermatology Therapeutics market in the U.S. is estimated at US$13.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$17.7 Billion by the year 2030 trailing a CAGR of 13.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Global Prescription Dermatology Therapeutics Market - Key Trends & Drivers Summarized

What Is Propelling the Shift Toward Prescription-Based Dermatology Therapies?

Prescription dermatology therapeutics represent a growing category of treatments designed to address moderate to severe skin conditions requiring medical intervention. Unlike over-the-counter skincare solutions, these therapies are used to treat chronic, inflammatory, infectious, and autoimmune dermatological conditions such as psoriasis, atopic dermatitis, rosacea, acne vulgaris, hidradenitis suppurativa, and skin cancers. With rising awareness of skin health, better access to dermatological care, and growing disease prevalence, the market has expanded significantly over the past decade.

Patients with persistent or recalcitrant conditions are increasingly being prescribed advanced topicals, oral retinoids, biologics, and systemic immunomodulators. The line between cosmetic and therapeutic dermatology is also blurring, with more patients seeking clinically validated solutions for pigmentation disorders, hair loss, and photodamage. As societal attitudes shift toward proactive skin management, even conditions once dismissed as “cosmetic nuisances” are being brought under the medical care umbrella.

Healthcare providers, including dermatologists, general physicians, and allergists, are also more inclined to prescribe specialty products amid greater disease awareness and improved diagnostic tools. Factors such as insurance coverage expansion, increased patient visits to dermatologists, and digital prescription platforms are amplifying prescription fill rates and enhancing adherence.

Which Scientific Advances and Molecule Innovations Are Reshaping Therapeutic Options?

The prescription dermatology market has seen a surge in new active pharmaceutical ingredients (APIs), targeted biologics, and delivery systems that have elevated the efficacy and safety profile of treatments. Traditional agents such as corticosteroids, retinoids, and antibiotics are now being complemented or replaced by novel immunomodulators, selective JAK inhibitors, and interleukin-targeting monoclonal antibodies that offer better disease control and fewer side effects.

Biologics such as dupilumab (for atopic dermatitis), secukinumab (for psoriasis), and adalimumab (for hidradenitis suppurativa) have dramatically improved outcomes in severe cases where topical agents fail. Small molecule therapies like PDE4 inhibitors and TYK2 blockers are also being evaluated and commercialized, especially for patients intolerant to biologics or with milder symptoms. The advent of biosimilars is reducing treatment costs and improving accessibility across different regions.

Formulation technologies have also advanced, with microsphere delivery, foam-based vehicles, and nanocarrier-enhanced topicals improving skin penetration, stability, and patient compliance. Companies are investing in personalized dermatology through pharmacogenomic screening and AI-guided therapeutic matching, especially for treatment-resistant conditions like seborrheic dermatitis or drug-resistant acne.

Which Patient Segments, Conditions, and Channels Are Shaping Market Dynamics?

Teenagers and young adults form a large proportion of the prescription dermatology market, particularly due to the widespread incidence of acne and acne-related scarring. Adult segments-especially those aged 30-55-are contributing to growth in therapeutic areas such as rosacea, melasma, and chronic urticaria. Geriatric patients, often managing comorbidities like diabetes or immune compromise, drive demand for antifungal, antiviral, and anti-inflammatory dermatological therapies.

The fastest-growing therapeutic segments include atopic dermatitis, psoriasis, and skin cancer. Environmental stressors, autoimmune triggers, and lifestyle changes are exacerbating chronic skin conditions globally. Urbanization, pollution, and prolonged screen exposure are also contributing to dermatological disorders related to oxidative stress and photoaging.

Prescription fulfillment is increasingly shifting toward digital and specialty pharmacy channels. Teledermatology is playing a central role in diagnosis and treatment initiation, particularly in underserved or remote markets. Specialty pharmacies, dermatology-focused chains, and digital platforms are improving compliance via automated refills, virtual consultations, and AI-enabled symptom tracking.

What Is Driving Growth in the Global Prescription Dermatology Therapeutics Market?

The growth in the global prescription dermatology therapeutics market is driven by the rising prevalence of chronic skin diseases, an expanding base of dermatology-trained physicians, and robust innovation in both drug molecules and delivery mechanisms. With skin health increasingly viewed as a core component of systemic health and quality of life, patient demand for effective, medically-supervised treatments is on the rise.

The commercialization of next-generation biologics and immunotherapies is reshaping treatment protocols, with faster disease control, reduced relapse rates, and improved patient outcomes. Regulatory approvals for biosimilars and novel topical formulations are enhancing affordability and expanding geographic access. In addition, growing investments in clinical trials and dermatology R&D pipelines are adding to therapeutic diversity.

Consumer digitalization and telemedicine adoption are supporting growth across prescription onboarding, refill logistics, and adherence monitoring. Markets in Asia-Pacific and Latin America are showing strong momentum due to growing dermatology infrastructure, rising disposable incomes, and awareness of dermatological health. As innovation, digital health, and patient-centric models converge, the prescription dermatology therapeutics market is positioned for strong global expansion over the next decade.

SCOPE OF STUDY:

The report analyzes the Prescription Dermatology Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs, Other Product Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • Almirall S.A.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Biofrontera AG
  • Cassiopea SpA (Cosmo Pharma)
  • Cipher Pharmaceuticals
  • Dermira, Inc. (a Lilly company)
  • Dr. Reddy's Laboratories
  • Galderma S.A.
  • Glenmark Pharmaceuticals
  • Leo Pharma A/S
  • Maruho Co., Ltd.
  • Mayne Pharma Group Ltd
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries
  • Viatris Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Prescription Dermatology Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rise in Skin Condition Prevalence Throws the Spotlight On Prescription Dermatology Innovations
    • Growth in Chronic Dermatological Disorders Drives Demand for Targeted Prescription Therapies
    • Advancements in Biologics and Small Molecule Drugs Strengthen Market for Specialty Skin Treatments
    • Expansion of Teledermatology Platforms Propels Prescription Accessibility and Market Penetration
    • Increasing Diagnosis of Psoriasis and Atopic Dermatitis Expands Addressable Therapeutic Opportunity
    • Regulatory Approvals of Novel Monoclonal Antibodies Drive Growth in Autoimmune Dermatology Segments
    • Rise in Personalized Medicine and Companion Diagnostics Spurs Use of Genotype-Specific Skin Treatments
    • Investment in AI-Based Skin Condition Screening Enhances Clinical Precision and Prescribing Confidence
    • Integration of Digital Prescriptions and Online Consultations Accelerates Treatment Initiation
    • Shift Toward Evidence-Based Dermatologic Guidelines Strengthens Business Case for Advanced Therapeutics
    • Rising Incidence of Skin Cancer and Actinic Keratosis Drives Demand for Prescription Oncology Dermatology Drugs
    • Growth in Aesthetic Dermatology Clinics Expands Use of Combination Prescription Therapies
    • Expansion of Patient Assistance Programs Improves Access to High-Cost Dermatological Medications
    • Increased Emphasis on Long-Term Disease Control and Remission Supports Adherence to Prescription Protocols
    • Launch of Novel Topicals With Advanced Delivery Mechanisms Drives Innovation in Non-Invasive Formulations
    • Regulatory Support for Fast-Track Designations Encourages Pipeline Acceleration in Dermatology Drugs
    • Rising Demand for Hormonal and Anti-Androgen Skin Therapies Boosts Female-Focused Dermatologic Prescriptions
    • Growth in Pediatric Dermatology Segments Spurs Market Entry of Age-Specific Prescription Formulations
    • Surge in Awareness Campaigns Around Eczema and Acne Fuels Demand for Physician-Driven Treatments
    • Collaborations With Dermatology Societies Strengthen Clinical Trial Networks and Therapeutic Development
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Prescription Dermatology Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Prescription Dermatology Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Prescription Dermatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Acne & Rosacea Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Acne & Rosacea Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Acne & Rosacea Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Psoriasis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Psoriasis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Psoriasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Dermatitis & Seborrhea Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Dermatitis & Seborrhea Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Dermatitis & Seborrhea Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Fungal Infection Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Fungal Infection Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Fungal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Skin Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Skin Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Skin Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Mail Order Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Mail Order Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Mail Order Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • JAPAN
    • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • CHINA
    • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: China 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • EUROPE
    • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Prescription Dermatology Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Prescription Dermatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • FRANCE
    • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: France 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • GERMANY
    • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Prescription Dermatology Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Prescription Dermatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • INDIA
    • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: India 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Prescription Dermatology Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Prescription Dermatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Prescription Dermatology Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Prescription Dermatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
  • AFRICA
    • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제